Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

NPJ Breast Cancer · 2026 · PMC13013833 · PMID 41688468

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

In the present correlative study from an investigator-initiated clinical trial, we report an enrichment in AR expression in HER2-low versus HER2-0 mTNBC, with a numerical trend in better prognosis observed among patients having both HER2-low and AR positivity.

also in 691 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.